Know Cancer

forgot password

A Phase II Randomized Study Of Dose-Dense Docetaxel And Cisplatin Every Two Weeks With Pegfilgrastim And Darbepoetin Alfa With And Without The Chemoprotector BNP7787 In Patients With Advanced Non-Small Cell Lung Cancer

Phase 2
18 Years
Not Enrolling
Anemia, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Neutropenia

Thank you

Trial Information

A Phase II Randomized Study Of Dose-Dense Docetaxel And Cisplatin Every Two Weeks With Pegfilgrastim And Darbepoetin Alfa With And Without The Chemoprotector BNP7787 In Patients With Advanced Non-Small Cell Lung Cancer



- Compare the incidence and severity of peripheral neuropathy in patients with stage IIIB
or IV non-small cell lung cancer treated with docetaxel and cisplatin with or without

- Compare the feasibility of these regimens, in terms of febrile neutropenia and
treatment delays, in these patients.

- Compare the objective response rate in patients treated with these regimens.


- Compare the survival and failure-free survival of patients treated with these regimens.

- Compare the toxicity profile of these regimens in these patients.

- Compare the incidence and severity of cisplatin-induced nephrotoxicity in patients
treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2
treatment arms.

- Arm I*: Patients receive docetaxel IV over 1 hour and cisplatin IV over 1 hour on day 1
and pegfilgrastim subcutaneously (SC) on day 2.

- Arm II*: Patients receive docetaxel, cisplatin, and pegfilgrastim as in arm I and
dimesna IV over 30 minutes on day 1.

NOTE: *In both arms, darbepoetin alfa is administered SC on day 1 of each course for
hemoglobin ≤ 11 g/dL.

In both arms, treatment repeats every 2 weeks for a total of 6 courses in the absence of
disease progression or unacceptable toxicity.

Patients are followed every 3 months for 1 year and then every 6 months for 2 years.

PROJECTED ACCRUAL: A total of 152 patients (76 per treatment arm) will be accrued for this
study within 18-20 months.

Inclusion Criteria


- Histologically or cytologically confirmed* non-small cell lung cancer of 1 of the
following subtypes:

- Squamous carcinoma

- Basaloid carcinoma

- Adenocarcinoma

- Bronchoalveolar carcinoma

- Adenosquamous carcinoma

- Large cell carcinoma

- Large cell neuroendocrine carcinoma

- Giant cell carcinoma

- Sarcomatoid carcinoma

- Non-small cell carcinoma not otherwise specified NOTE: *Histologic or cytologic
confirmation of recurrence is required for patients who have undergone prior
complete resection

- Stage IIIB disease due to malignant pleural effusion OR stage IV disease

- Measurable disease

- At least 1 unidimensionally measurable lesion at least 20 mm by conventional
techniques OR at least 10 mm by spiral CT scan

- The following are considered nonmeasurable disease:

- Bone lesions

- Brain metastases or leptomeningeal disease

- Ascites

- Pleural/pericardial effusion

- Abdominal masses not confirmed and followed by imaging techniques

- Cystic lesions

- Tumor lesions situated in a previously irradiated area

- Brain metastases are allowed provided patient is neurologically stable and off



- 18 and over

Performance status

- ECOG 0-1

Life expectancy

- Not specified


- Granulocyte count ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3


- Bilirubin ≤ 1.5 mg/dL

- AST ≤ 1.5 times upper limit of normal (ULN)

- Alkaline phosphatase ≤ 2.5 times ULN


- Creatinine ≤ ULN


- Not pregnant or nursing

- Fertile patients must use effective contraception

- No grade 2 or greater neuropathy


Biologic therapy

- No other concurrent growth factors


- No prior chemotherapy

- No other concurrent chemotherapy

Endocrine therapy

- See Disease Characteristics

- No concurrent hormonal therapy except steroids administered for adrenal failure,
hormones for non-cancer-related conditions (e.g., insulin for diabetes), or
intermittent dexamethasone as an antiemetic


- See Disease Characteristics

- Prior radiotherapy allowed for brain metastases only

- No concurrent palliative radiotherapy


- See Disease Characteristics

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:


Outcome Description:

Toxicity profile w/ emphasis on incidence and severity of peripheral neuropathy, febrile neutropenia, and nephrotoxicity

Outcome Time Frame:

12 weeks

Safety Issue:


Principal Investigator

Antonius A. Miller, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Comprehensive Cancer Center of Wake Forest University


United States: Food and Drug Administration

Study ID:




Start Date:

August 2004

Completion Date:

April 2009

Related Keywords:

  • Anemia
  • Drug/Agent Toxicity by Tissue/Organ
  • Lung Cancer
  • Neutropenia
  • drug/agent toxicity by tissue/organ
  • anemia
  • neutropenia
  • stage IV non-small cell lung cancer
  • stage IIIB non-small cell lung cancer
  • recurrent non-small cell lung cancer
  • squamous cell lung cancer
  • large cell lung cancer
  • adenocarcinoma of the lung
  • bronchoalveolar cell lung cancer
  • adenosquamous cell lung cancer
  • Anemia
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Neutropenia



University of Chicago Cancer Research Center Chicago, Illinois  60637
Duke Comprehensive Cancer Center Durham, North Carolina  27710
CCOP - Christiana Care Health Services Wilmington, Delaware  19899
CCOP - Illinois Oncology Research Association Peoria, Illinois  61602
Methodist Medical Center of Illinois Peoria, Illinois  61636
Elliot Regional Cancer Center Manchester, New Hampshire  03103
Holden Comprehensive Cancer Center at University of Iowa Iowa City, Iowa  52242-1002
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Columbus, Ohio  43210-1240
Louis A. Weiss Memorial Hospital Chicago, Illinois  60640
Veterans Affairs Medical Center - Baltimore Baltimore, Maryland  21201
Veterans Affairs Medical Center - Dallas Dallas, Texas  75216
SUNY Upstate Medical University Hospital Syracuse, New York  13210
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas Dallas, Texas  75390
CCOP - Hematology-Oncology Associates of Central New York East Syracuse, New York  13057
Hematology Oncology Associates of the Quad Cities Bettendorf, Iowa  52722
Wayne Memorial Hospital, Incorporated Goldsboro, North Carolina  27534
Greenebaum Cancer Center at University of Maryland Medical Center Baltimore, Maryland  21201
New Hampshire Oncology-Hematology, PA - Hooksett Hooksett, New Hampshire  03106
Lenoir Memorial Cancer Center Kinston, North Carolina  28503-1678
Zimmer Cancer Center at New Hanover Regional Medical Center Wilmington, North Carolina  28402-9025
University of Illinois Cancer Center Chicago, Illinois  60612-7243
CCOP - Nevada Cancer Research Foundation Las Vegas, Nevada  89109-2306
Oncology/Hematology Associates of Central Illinois, P.C. Peoria, Illinois  61602
Parkland Memorial Hospital Dallas, Texas  75235
Veterans Affairs Medical Center - Chicago Westside Hospital Chicago, Illinois  60612
University Medical Center of Southern Nevada Las Vegas, Nevada  89102
Cancer Institute of New Jersey at the Cooper University Hospital - Voorhees Camden, New Jersey  08103
Beebe Medical Center Lewes, Delaware  19958
St. Francis Hospital Wilmington, Delaware  19805
St. Joseph Medical Center Bloomington, Illinois  61701
Graham Hospital Canton, Illinois  61520
Memorial Hospital Carthage, Illinois  62321
Eureka Community Hospital Eureka, Illinois  61530
Galesburg Cottage Hospital Galesburg, Illinois  61401
Galesburg Clinic Galesburg, Illinois  61401
Mason District Hospital Havana, Illinois  62644
Hopedale Medical Complex Hopedale, Illinois  61747
Kewanee Hospital Kewanee, Illinois  61443
McDonough District Hospital Macomb, Illinois  61455
BroMenn Regional Medical Center Normal, Illinois  61761
Community Cancer Center Normal, Illinois  61761
Community Hospital of Ottawa Ottawa, Illinois  61350
Cancer Treatment Center at Pekin Hospital Pekin, Illinois  61554
OSF St. Francis Medical Center Peoria, Illinois  61637
Proctor Hospital Peoria, Illinois  61614
Illinois Valley Community Hospital Peru, Illinois  61354
Perry Memorial Hospital Princeton, Illinois  61356
St. Margaret's Hospital Spring Valley, Illinois  61362
Union Hospital Cancer Center at Union Hospital Elkton MD, Maryland  21921
Creighton University Medical Center Omaha, Nebraska  68131-2197
Charles R. Wood Cancer Center at Glens Falls Hospital Glens Falls, New York  12801
Community General Hospital of Greater Syracuse Syracuse, New York  13215
Oncology Hematology Associates of Central Illinois - Ottawa Ottawa, Illinois  61350
Missouri Baptist Cancer Center St. Louis, Missouri  63131
Cancer Resource Center - Lincoln Lincoln, Nebraska  68510
Cancer Care Associates - Mercy Campus Oklahoma City, Oklahoma  73120
Methodist Cancer Center at Methodist Hospital - Omaha Omaha, Nebraska  68114
Zale Lipshy University Hospital Dallas, Texas  75235-7786
McLeod Regional Medical Center Florence, South Carolina  29501
Arch Medical Services, Incorporated at Center for Cancer Care Research Saint Louis, Missouri  63141
Lakes Region General Hospital Laconia, New Hampshire  03246
Faxton Regional Cancer Center Utica, New York  13502
El Camino Hospital Mountain View, California  94040
St. Mary's Regional Cancer Center at St. Mary's Medical Center Huntington, West Virginia  25702